Japan Issues New Guidance On Regenerative Medicine
This article was originally published in PharmAsia News
To encourage development of treatments and medical devices in the Regenerative Medicine area, Japan's Ministry of Health, Labor and Welfare issued new guidance regarding quality and safety in RM development. A follow-up to previous guidance issued in 2000, the new guidance listed points for donor selection, screening of rejections, virus deactivation and removal, and quality management in cellular reproduction. Regarding autologous cells, the guidance calls for individualized measures to prevent confusion and cross contamination. In October 2007, autologous cultured epidermis JACE made by Aichi-based Japan Tissue Engineering Co., received government approval to treat serious burns. (Click for more-Japanese language
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.